Sequah Medicine Company

Nanoscope Therapeutics Continues Leadership Growth; Welcomes Accomplished Finance and Biotech Leader Glenn Sblendorio as Chairman of the Board

Retrieved on: 
Monday, December 4, 2023
Sequah Medicine Company, Hope, Entrepreneurship, CFO, Patient, EVP, Roche, Physician, Knowledge, Retina, Management, Atomic de Broglie microscope

DALLAS, Dec. 4, 2023 /PRNewswire/ -- Nanoscope Therapeutics (Nanoscope), a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced the appointment of Glenn Sblendorio as Chairman of the Board, effective immediately. With more than 30 years of exemplary experience marked by extensive executive leadership in the ophthalmic industry, Mr. Sblendorio will support Nanoscope in reaching its strategic vision.

Key Points: 
  • DALLAS, Dec. 4, 2023 /PRNewswire/ -- Nanoscope Therapeutics (Nanoscope), a clinical-stage biotechnology company developing gene therapies for inherited retinal diseases, today announced the appointment of Glenn Sblendorio as Chairman of the Board, effective immediately.
  • With more than 30 years of exemplary experience marked by extensive executive leadership in the ophthalmic industry, Mr. Sblendorio will support Nanoscope in reaching its strategic vision.
  • Mr. Sblendorio remarked on his appointment, "I am honored to join Nanoscope as Chairman of the Board.
  • Nanoscope CEO and Co-Founder Sulagna Bhattacharya expressed enthusiasm about the appointment, stating, "We are elated to welcome Glenn Sblendorio as our Chairman of the Board.

Mineralys Therapeutics Expands its Board of Directors with Appointments of Glenn Sblendorio and Daphne Karydas

Retrieved on: 
Thursday, September 14, 2023
OSI Pharmaceuticals, Chronic kidney disease, Biotechnology, Allergan, Finance, Amicus Therapeutics, Fairleigh Dickinson University, Strategic management, Hypertension, Sequah Medicine Company, Massachusetts Institute of Technology, Patient, Flare, Chemical engineering, Pace University, Harvard Business School, Intercept Pharmaceuticals, Astellas Pharma, Growth, Therapy, CKD, Daphne, Pharmaceutical industry, Management

In addition, Mineralys announced that Takeshi Takahashi of Catalys Pacific has stepped down from the Board, effective September 12, 2023.

Key Points: 
  • In addition, Mineralys announced that Takeshi Takahashi of Catalys Pacific has stepped down from the Board, effective September 12, 2023.
  • “We are excited to have Daphne and Glenn join our Board and support Mineralys' efforts to develop innovative medicines aimed to improve the lives of patients with cardiorenal disorders.
  • Ms. Karydas has previously served on the boards of directors at Elicio Therapeutics, LogicBio Therapeutics, Inc., and Eucrates Biomedical Acquisition Corp. Ms. Karydas received a B.A.
  • Mr. Sblendorio also serves as a member of the board of directors of Intercept Pharmaceuticals, Inc. and as a member of the board of directors of Amicus Therapeutics, Inc. Mr. Sblendorio received his B.B.A.

Lexicon Elects Diane E. Sullivan to Board of Directors

Retrieved on: 
Friday, July 28, 2023
GSK plc, Marketing, AstraZeneca, Sequah Medicine Company, Acquisition, Novartis, Avanos Medical, Wyeth, Lexicon, Pharmaceutical industry, Amarin, Pfizer

THE WOODLANDS, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Diane E. Sullivan has been elected to its Board of Directors.

Key Points: 
  • THE WOODLANDS, Texas, July 28, 2023 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Diane E. Sullivan has been elected to its Board of Directors.
  • Ms. Sullivan brings extensive commercialization, strategy, and market access experience to the Lexicon Board of Directors.
  • “We are grateful to Frank for his service on the Board of Directors and appreciate his contributions to the company’s progress,” said Ray Debbane, Lexicon’s Board Chair.
  • We are very excited to have Diane join the Board of Directors.”

Sarissa Capital Urges Alkermes Shareholders to Vote “FOR” Sarah Schlesinger and “WITHHOLD” Incumbent Director Richard Gaynor

Retrieved on: 
Wednesday, June 28, 2023
Finance, Business, Banking, Professional Services, Other Professional Services, BLUE, Shareholder, Internet, Glenview Capital Management, Telephone, Annual, Annual Meetings of the International Monetary Fund and the World Bank Group, Wall Street, ALKS, Sequah Medicine Company, ARIAD Pharmaceuticals, ISS, Alkermes (company), Management, Security (finance), Alkermes, Sarissa

Shareholder pressure, including from Sarissa, has only incrementally moved the company in the right direction the last few years.

Key Points: 
  • Shareholder pressure, including from Sarissa, has only incrementally moved the company in the right direction the last few years.
  • If shareholders are not added to the board, we fear that Pops will continue to run the company as he pleases and never address its fundamental issues.
  • The board steadfastly refuses to add our nominees, including Sarah Schlesinger, who the Nom-Gov committee at Alkermes previously acknowledged would be a qualified board candidate and who ISS recommended that shareholders vote “FOR”.
  • Shareholders face an important decision at the upcoming Alkermes annual shareholder meeting.

Anaemia Drugs Market to Grow Exponentially by 2029 Says Brandessence Market Research

Retrieved on: 
Thursday, June 15, 2023
Insurance, GSK plc, Prevalence, Anemia, Amgen, Special, Ageing, Woman, Pfizer, Research, USD, Kidney, Sequah Medicine Company, Anti-transglutaminase antibodies, Hospital, Traction, Novartis, DSM-IV codes, Investment, Folate, Nature, Patient, Blood, Patent, Vitamin B12, Porter's five forces analysis, Growth, Conditional sentence, Allergan, Inc., Agent handling, AbbVie, Health, Malnutrition, Therapy, Skin, Fatigue, Dietary supplement, Generic drug, Pharmaceutical industry, Salt, Health care, Fine chemical, Medical device

The business intelligence report on Anaemia Drugs Market by Brandessence Market Research is curated with an aim to empower the businesses with holistic knowledge on this industry.

Key Points: 
  • The business intelligence report on Anaemia Drugs Market by Brandessence Market Research is curated with an aim to empower the businesses with holistic knowledge on this industry.
  • Anaemia Drugs Market to grow with a CAGR of 11.20% over 2022-2029.
  • Anaemia Drugs Market was valued at USD 26292.3 Million in 2018 and expected to reach USD 55279.2 Million by 2025 with the CAGR of 11.20% over the forecast period.
  • As the number of elderly individuals increases, the demand for anaemia drugs also rises, thereby bolstering market growth.

Anaemia Drugs Market to Grow Exponentially by 2029 Says Brandessence Market Research

Retrieved on: 
Thursday, June 15, 2023
Insurance, GSK plc, Prevalence, Anemia, Amgen, Special, Ageing, Woman, Pfizer, Research, USD, Kidney, Sequah Medicine Company, Anti-transglutaminase antibodies, Hospital, Traction, Novartis, DSM-IV codes, Investment, Folate, Nature, Patient, Blood, Patent, Vitamin B12, Porter's five forces analysis, Growth, Conditional sentence, Allergan, Inc., Agent handling, AbbVie, Health, Malnutrition, Therapy, Skin, Fatigue, Dietary supplement, Generic drug, Pharmaceutical industry, Salt, Health care, Fine chemical, Medical device

The business intelligence report on Anaemia Drugs Market by Brandessence Market Research is curated with an aim to empower the businesses with holistic knowledge on this industry.

Key Points: 
  • The business intelligence report on Anaemia Drugs Market by Brandessence Market Research is curated with an aim to empower the businesses with holistic knowledge on this industry.
  • Anaemia Drugs Market to grow with a CAGR of 11.20% over 2022-2029.
  • Anaemia Drugs Market was valued at USD 26292.3 Million in 2018 and expected to reach USD 55279.2 Million by 2025 with the CAGR of 11.20% over the forecast period.
  • As the number of elderly individuals increases, the demand for anaemia drugs also rises, thereby bolstering market growth.

Kymera Appoints Jeremy Chadwick, Ph.D., as Chief Operating Officer

Retrieved on: 
Monday, May 22, 2023
University, Data management, BS, Senior, Statistics, Simon de Montfort, 6th Earl of Leicester, TPD, Research, Doctor of Philosophy, Sequah Medicine Company, Shire (pharmaceutical company), Patient, Vertex Pharmaceuticals, United Kingdom, Biostatistics, Therapy, Takeda Pharmaceutical Company, Fine chemical, Medical device, Mathematics, Takeda

WATERTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer.

Key Points: 
  • WATERTOWN, Mass., May 22, 2023 (GLOBE NEWSWIRE) -- Kymera Therapeutics, Inc. (NASDAQ: KYMR), a clinical-stage biopharmaceutical company advancing targeted protein degradation (TPD) to deliver novel small molecule protein degrader medicines, today announced the appointment of Jeremy Chadwick, Ph.D., as Chief Operating Officer.
  • Dr. Chadwick joins Kymera with extensive experience overseeing global development operations, regulatory and program management at a range of biopharmaceutical companies.
  • As a member of the Company’s senior management team, Dr. Chadwick will develop and execute near-term and long-range strategies to maximize the impact of Kymera’s expanding pipeline.
  • He earned his MS and PhD in Statistics from the University of London and a BS in Mathematics from Demontfort University in the United Kingdom.

Boyden United States Welcomes Business Leader Leslie C. Rohrbacker as a Partner in Summit

Retrieved on: 
Wednesday, May 17, 2023
Seton Hall University School of Law, Human resources, Simmons University, Employment, Partnership, Incubator, Health care, Risk management, Library and information science, Woman, Sequah Medicine Company, BAL, Novartis, Embrace (non-profit), Certification, DEI, Growth, Hospital, Information science, Management, Boston College

Summit, NJ, May 17, 2023 (GLOBE NEWSWIRE) -- Boyden, a premier leadership and talent advisory firm with more than 70 offices in over 45 countries, is delighted to welcome Leslie Rohrbacker to its partnership in the United States, based in Summit.

Key Points: 
  • Summit, NJ, May 17, 2023 (GLOBE NEWSWIRE) -- Boyden, a premier leadership and talent advisory firm with more than 70 offices in over 45 countries, is delighted to welcome Leslie Rohrbacker to its partnership in the United States, based in Summit.
  • Commenting on her appointment, Leslie said, “I am excited to bring my commercial, legal and people expertise into executive search and leadership consulting.
  • Leslie then advanced to Chief Operating Officer at BAL, another global corporate law firm.
  • Leslie is also CEO and Founder of a women-owned consulting firm focused on talent and risk management.

Eterna Therapeutics Acquires Allogeneic Immuno-Oncology Platform from Exacis Biotherapeutics

Retrieved on: 
Tuesday, May 2, 2023
DNA, Gene editing, Bone marrow, Cancer, Coronavirus Scientific Advisory Board, NK, Cell, Messenger, Sequah Medicine Company, Acquisition, Patient, Physician, ERNA, Virus, Vaccine, Pharmaceutical industry, Eterna, Novartis, Research

CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. (Nasdaq: ERNA) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the acquisition of the global immuno-oncology platform of Exacis Biotherapeutics (“Exacis”). The acquisition complements Eterna’s core business with a pipeline of allogeneic immuno-oncology products under development for the treatment of hematologic and solid tumors and provides Eterna with an exclusive global license to produce an unlimited number of mRNA-engineered natural killer (NK) and T-cell therapies derived from induced pluripotent stem cells (iPSCs).

Key Points: 
  • CAMBRIDGE, Mass., May 02, 2023 (GLOBE NEWSWIRE) -- Eterna Therapeutics Inc. ( Nasdaq: ERNA ) (“Eterna” or the “Company”), a life science company committed to realizing the potential of mRNA cell engineering to provide patients with transformational new medicines, today announced the acquisition of the global immuno-oncology platform of Exacis Biotherapeutics (“Exacis”).
  • “We are excited to bring this powerful platform into Eterna.
  • With Exacis’ pipeline of engineered iPSC-derived cell therapy candidates, we believe Eterna is well-positioned to develop more effective, targeted and highly differentiated medicines to treat cancer,” said Matt Angel, Ph.D., Chief Executive Officer and President of Eterna.
  • Eterna plans to use Exacis’ platform to develop engineered cell therapies containing genomic edits designed to enhance their performance.

Strand Therapeutics Appoints Colleen Wilson as Chief People Officer

Retrieved on: 
Monday, April 24, 2023
Research, Genetics, Clinical Trials, Biotechnology, Health, Pharmaceutical, Other Science, Science, Oncology, Omni, Vaccine, Human resources, University, Therapy, Melinta Therapeutics, Culture, Head, Cancer, Babson College, MBA, Multimedia, MIT, Human, Messenger, Wilson, Genzyme, Targanta Therapeutics Corporation, Patient, HR, Sequah Medicine Company, Growth, SVP, Management, Pharmaceutical industry

Strand Therapeutics , the programmable mRNA company developing curative therapies for cancer and other diseases, today announced the appointment of Colleen Wilson as Chief People Officer.

Key Points: 
  • Strand Therapeutics , the programmable mRNA company developing curative therapies for cancer and other diseases, today announced the appointment of Colleen Wilson as Chief People Officer.
  • View the full release here: https://www.businesswire.com/news/home/20230424005276/en/
    “We’re thrilled to welcome Colleen, a highly talented industry veteran to the Strand executive team,” said Jake Becraft, Ph.D., CEO & Co-Founder, Strand Therapeutics.
  • Ms. Wilson has also held HR roles at Infinity Pharmaceuticals, Genzyme Corporation, Targanta Therapeutics (acquired by Medicines Company) and Therion Biologics.
  • Strand Therapeutics is a next-generation biotechnology company committed to transforming the lives of patients by developing first-in-class programmable mRNA therapeutics.